Technical Analysis for PBYI - Puma Biotechnology Inc

Grade Last Price % Change Price Change
grade F 7.44 -16.87% -1.51
PBYI closed down 16.87 percent on Thursday, December 5, 2019, on 1.99 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical PBYI trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
20 DMA Support Bullish -16.87%
Slingshot Bullish Bullish Swing Setup -16.87%
Wide Bands Range Expansion -16.87%
Bearish Engulfing Bearish -20.43%
Stochastic Sell Signal Bearish -20.43%

Older signals for PBYI ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Puma Biotechnology, Inc., a development stage biopharmaceutical company, engages in the acquisition, development, and licensing of products for the treatment of various forms of cancer. Its drug candidates include PB272 (neratinib (oral)) for the treatment of advanced breast cancer patients and non-small cell lung cancer patients; and PB272 (neratinib (intravenous)) for the treatment of advanced cancer patients. The company is also involved in developing PB357, an orally administered agent, which is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Chemistry Cancer Chemical Compounds Organic Compounds Non Small Cell Lung Cancer Chloroarenes Pyridines Tyrosine Kinase Receptors Protein Kinase Inhibitor Epidermal Growth Factor Receptor Aromatic Amines Her2/Neu Advanced Breast Cancer Nitriles Treatment Of Advanced Breast Cancer Treatment Of Various Forms Of Cancer

Is PBYI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Indicators
Indicator Value
52 Week High 43.9
52 Week Low 6.26
Average Volume 1,652,000
200-Day Moving Average 17.46
50-Day Moving Average 8.29
20-Day Moving Average 8.75
10-Day Moving Average 9.22
Average True Range 0.84
ADX 23.07
+DI 24.35
-DI 26.91
Chandelier Exit (Long, 3 ATRs ) 8.59
Chandelier Exit (Short, 3 ATRs ) 8.77
Upper Bollinger Band 10.30
Lower Bollinger Band 7.20
Percent B (%b) 0.08
BandWidth 35.39
MACD Line 0.23
MACD Signal Line 0.28
MACD Histogram -0.0505
Fundamentals Value
Market Cap 276.81 Million
Num Shares 37.2 Million
EPS -8.14
Price-to-Earnings (P/E) Ratio -0.91
Price-to-Sales 0.00
Price-to-Book 37.58
PEG Ratio 0.03
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.90
Resistance 3 (R3) 10.14 9.57 9.49
Resistance 2 (R2) 9.57 8.94 9.45 9.35
Resistance 1 (R1) 8.50 8.55 8.22 8.26 9.22
Pivot Point 7.93 7.93 7.78 7.81 7.93
Support 1 (S1) 6.86 7.30 6.58 6.62 5.66
Support 2 (S2) 6.29 6.91 6.17 5.53
Support 3 (S3) 5.22 6.29 5.39
Support 4 (S4) 4.98